Searched for
ANIL SATWANI
Symbiotec Pharmalab plans IPO to boost specialty pharma marketSymbiotec Pharmalab, a leading API manufacturer, is planning an IPO. The company targets a valuation of about $1 billion. The IPO aims to r...- Indian drug firms cheer dexamethasone efficacy on severe COVID-19 patientsM P Gupta, general manager of Mahima Lifesciences, a Chandigarh-based steroid API maker, said the company was expecting a jump in raw mater...
- MOPE and InvAscent buy 70% in Symbiotec for $100 mPE fund Actis sells the stake in API maker, valuing company at $140 m.
- Actis to buy 25% in steroids maker Symbiotec Pharmalab for Rs 300 crorePrivate equity fund Actis is looking to purchase more than 25% stake in cortico steroids maker Symbiotec Pharmalab for around $50 million.
- Franklin Templeton PE invests Rs 45 cr in drug-maker Symbiotec PharmalabSymbiotec is engaged in research, development, manufacturing and marketing of research-based active pharmaceutical ingredients for corticos...
Load More